EQ · Equillium, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-10-26 | Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 |
| 2026-10-06 | Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference |
| 2026-10-06 |
AhR Activation Stabilizes Inflammatory Crosstalk and Promotes Barrier Repair in An Intestinal Co-Culture Model <span>Rosa Quinn Closser, et. al.</span> <span>La Jolla Immunology Conference</span> <span>2026</span>
Rosa Quinn Closser, et. al. Conference: La Jolla Immunology Conference Year: 2026 |
| 2026-10-05 | Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 |
| 2026-09-29 | Equillium Announces Poster Presentations at the 7th International AHR Conference |
| 2026-09-29 |
Selective AhR Activation Suppresses Epithelial Chemokine Production and Promotes Barrier Repair Responses in Translational Models of Ulcerative Colitis<span>Valeria Marrocco, et. al.</span><span>7th International AHR Conference</span><span>2026</span>
Valeria Marrocco, et. al. Conference: 7th International AHR Conference Year: 2026 |
| 2026-09-29 |
AhR Modulation by EQ504 Restores Immune Balance by Suppressing Pathogenic Th17/M1 Responses While Enhancing Regulatory Pathways<span>Jeanette Ampudia, et. al.</span><span> 7th Internation AHR Conference </span><span>2026</span>
Jeanette Ampudia, et. al. Conference: 7th Internation AHR Conference Year: 2026 |
| 2026-09-16 | Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum |
| 2026-09-02 | Equillium to Participate in Upcoming Investor Conferences |
| 2026-08-13 | Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights |
| 2026-06-02 | Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-28 | Equillium to Participate in the 2026 Jefferies Global Healthcare Conference |
| 2026-05-20 | Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis |
| 2026-05-13 | Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights |
| 2026-05-01 | Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-20 | Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event |
| 2026-04-20 |
EQ504, a Potent AhR Modulator, Promotes Epithelial Repair and Barrier Restoration Compared to Clinically Validated AhR Agonists<span>Mary Casis, et al.</span><span> American Association of Immunology Conference </span><span>2026</span>
Mary Casis, et al. Conference: American Association of Immunology Conference Year: 2026 |
| 2026-04-16 |
EQ504: A Novel AhR Modulator That Promotes Immune Tolerance Through IL-10 & IL-22 Cytokine Release<span>Jeanette Ampudia, et. al.</span><span> American Association for Immunologists Conference </span><span>2026</span>
Jeanette Ampudia, et. al. Conference: placeholder Year: 2026 |
| 2026-04-08 | Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists |
| 2026-04-02 | Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-25 | Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights |
| 2026-03-18 | Equillium to Participate in the 38th Annual Roth Conference |
| 2026-03-13 |
Equillium Announces $35 Million Financing with RA Capital Management
Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA JOLLA, Calif., March 13, 2026 (GLOBE NEWSWIRE) - Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a definitive securities purchase agreement with RA Capital Management that will provide approximately $35 million in gross proceeds to Equillium. Pursuant to the terms of the securities purchase agreement, the Company will issue approximately 18.9 million shares of its common stock (including shares of common stock underlying pre-funded warrants), representing a purchase price of $1.854 for each share of common stock (which represents the average closing price of the Company’s common stock for the five trading days immediately prior to the |
| 2026-02-25 |
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) - Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About Equillium Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via |
| 2026-02-02 |
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) - Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $1.42, Equillium’s closing stock price on January 30, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to |